Supplementary Figure S4 from Combined MEK and BCL-2/X&lt;sub&gt;L&lt;/sub&gt; Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient–Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness